tbuckley/cabot-search huggingface dataset:
Effect of reimbursement changes on erythropoiesis‐stimulating agent utilization and transfusions
Authors: Gregory Hess, Robert J. Nordyke, Jerrold Hill, Scott Hulnick
Journal: American Journal of Hematology (2010)

Cancer patients frequently develop chemotherapy-induced anemia, which can be treated with erythropoiesis-stimulating agents. These agents have shifted the standard of chemotherapy-induced anemia treatment away from the previous mainstay of red blood cell transfusions. In July 2007, the Centers for Medicare and Medicaid Services issued a National Coverage Decision restricting reimbursement for erythropoiesis-stimulating agents to those chemotherapy patients who have hemoglobin levels <10 g/dL at initiation of therapy. This decision was hypothesized to place a greater reliance on transfusions for chemotherapy-induced anemia treatment. This observational study examined transfusions and erythropoiesis-stimulating agent utilization rates within defined episodes of chemotherapy care using electronic medical records from seven practices consisting of 39 sites of care across seven states. We compared the frequency of myelosuppressive chemotherapy treatment, erythropoiesis-stimulating agent administrations, and red blood cell transfusions before and after the National Coverage Decision in oncology patients with chemotherapy-induced anemia. Although exposure to myelosuppressive chemotherapy was not different, erythropoiesis-stimulating agent administrations significantly decreased and blood transfusions significantly increased after implementation of the National Coverage Decision. The 31% increase in transfusions for patients aged 65 years and older was significant (P = 0.007) and higher than the 8% increase for patients younger than 65 years (P = 0.358). Changes in practice patterns for chemotherapy-induced anemia treatment that followed the Centers for Medicare and Medicaid Services reimbursement decision for erythropoiesis-stimulating agents seem to be impacting practice patterns. Further research is necessary to determine whether these changes represent a widespread and durable shift in patient treatment.
Recognition and Significance of Pathological T-Wave Inversions in Athletes
Authors: Frédéric Schnell, Nathan Riding, Rory O’Hanlon, Pierre Axel Lentz, Erwan Donal, Gaelle Kervio, David Matelot, Guillaume Leurent, Stéphane Doutreleau, Laurent Chevalier, Sylvain Guerard, Mathew G. Wilson, François Carré
Journal: Circulation (2014)

Background— Pathological T-wave inversion (PTWI) is rarely observed on the ECG of healthy athletes, whereas it is common in patients with certain cardiac diseases. All ECG interpretation guidelines for use within athletes state that PTWI (except in leads aVR, III and V1 and in V1–V4 when preceded by domed ST segment in asymptomatic Afro-Caribbean athletes only) cannot be considered a physiological adaptation. The aims of the present study were to prospectively determine the prevalence of cardiac pathology in athletes presenting with PTWI, and to examine the efficacy of cardiac magnetic resonance in the work-up battery of further examinations. Methods and Results— Athletes presenting with PTWI (n=155) were investigated with clinical examination, ECG, echocardiography, exercise testing, 24h Holter ECG, and cardiac magnetic resonance. Cardiac disease was established in 44.5% of athletes, with hypertrophic cardiomyopathy (81%) the most common pathology. Echocardiography was abnormal in 53.6% of positive cases, and cardiac magnetic resonance identified a further 24 athletes with disease. Five athletes (7.2%) considered normal on initial presentation subsequently expressed pathology during follow-up. Familial history of sudden cardiac death and ST-segment depression associated with PTWI were predictive of cardiac disease. Conclusions— PTWI should be considered pathological in all cases until proven otherwise, because it was associated with cardiac pathology in 45% of athletes. Despite echocardiography identifying pathology in half of these cases, cardiac magnetic resonance must be considered routine in athletes presenting with PTWI with normal echocardiography. Although exclusion from competitive sport is not warranted in the presence of normal secondary examinations, annual follow-up is essential to ascertain possible disease expression.
New Therapies for Castration-Resistant Prostate Cancer
Authors: Dan L. Longo
Journal: New England Journal of Medicine (2010)

On April 29, 2010, the Food and Drug Administration (FDA) approved a new immunotherapy, sipuleucel-T, for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer. Traditionally, immune-based therapies have been categorized according to whether the agent has direct antitumor effects (so-called passive immunotherapy) or stimulates a host antitumor response (active immunotherapy) and whether the agent elicits a general increase in immune activation (nonspecific) or an immune response based on tumor recognition (specific). Sipuleucel-T is a form of active specific immunotherapy.The sipuleucel-T intervention involves harvesting the patient's peripheral-blood mononuclear cells (PBMCs), culturing them with a chimeric protein . . .
A Method for Endoscopic Electroresection of Sessile Colonic Polyps
Authors: P. Deyhle, F. Largiadèr, S. Jenny, I. Fumagalli
Journal: Endoscopy (1973)

The endoscopic removal of sessile polyps in the proximal colon in man by a diathermy loop may cause perforation. Injection of a fluid depot under the colonic mucosa in dogs prevents sufficiently coagulation of the underlying intestinal wall during diathermic removal of mucosal specimens. With this method 7 sessile colonic polyps in man were endoscopically removed with a diathermy loop without complications.
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Authors: Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward D. Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney
Journal: Blood (2008)
Identification of patients when taking blood: Author's reply
Authors: M. Contreras
Journal: BMJ (1991)

trying to push a used needle into a movable sheath and then turning the syringe upwards to let the sheath cover the needle could lead to "chasing" the sheath across the surface of the table, flipping the sheath off on to the floor, and injuring a bystander in the process.The Saf-T-Cap and other similar devices would still require a steady hand and eye to put the needle into the sheath at the first attempt.There might also be the temptation to steady the device with the other hand while using it, thereby increasing the risk of a needlestick injury to that hand.We accept that if there are situations where recapping is unavoidable, the Saf-T-Cap is simple enough and better in many aspects than some of the more complicated alternative multiple hole devices- some with cutter attachments to remove the needle from the syringe.The advice of the Centers for Disease Control and the British Medical Association,2 that re- sheathing is generally inadvisable, is still sound.We would also support the requirement for all sharps containers to meet British Safety standards (7320).Rather than recommending resheathing we recommend the adequate provision, use, and disposal of robust sharps containers at suitable intervals and a programme to educate all staff in the safe disposal of sharps, as required by the Control of Substances Hazardous to Health Regu- lations 1988.
UNC Cancer Center Receives Comprehensive Designation
Authors: M. E. Newman
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article UNC Cancer Center Receives Comprehensive Designation Get access Michael E. Newman Michael E. Newman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 15, 1 August 1990, Pages 1243–1244, https://doi.org/10.1093/jnci/82.15.1243 Published: 01 August 1990
Letter: Antibody response to A-England-42-72 influenza vaccine.
Authors: L Picciotto, E Romano, G Ruggiero, B Galanti, G Giusti
Journal: BMJ (1973)

decision to reduce the birth rate, irrespective of -the consequences such *masures may have on the life dt an individual.When ad- vising procedures wvhich "penranently" deny procreation, it is important that the physician be -not carried away with his own enthusiasm for the operation and by his public-spiritedness.The paramount concern, as always, should be the future happiness and emotional stability of his patient.-Weare, etc.,
Walter Reed: Material Wanted
Authors: WILLIAM B. BEAN
Journal: Annals of Internal Medicine (1971)

Letters and Comments1 February 1971Walter Reed: Material WantedWILLIAM B. BEAN, M.D.WILLIAM B. BEAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-74-2-300_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: I am editing the works, papers, and letters of Walter Reed of yellow fever fame. I would appreciate anybody with original documentary material, letters, papers, or other primary source material bringing them to my attention.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: WILLIAM B. BEAN, M.D.Affiliations: Department of Internal Medicine University Hospitals The University of Iowa Iowa City, Iowa 52240 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1971Volume 74, Issue 2Page: 300-300KeywordsFevers ePublished: 1 December 2008 Issue Published: 1 February 1971 PDF downloadLoading ...
Scent, Sounds, Leaves, Life
Authors: Joshua Latzman
Journal: Annals of Internal Medicine (2007)

Ad Libitum2 October 2007Scent, Sounds, Leaves, LifeJoshua Latzman, MDJoshua Latzman, MDFrom Manhasset, NY 11030.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-7-200710020-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Beyond twilight you whispersomething about the scentEvergreen trees exude in winter.My eyes shut, I can imagineyour lone dimple creasing inwards.You, almost silently, speak of asymphony, winds racing arounda track of leaves in timewith the rhythm of my breath,the scratching of the tree.An intrusive phonograph rapsthe crackling ice of our window,half calling me from slumber,delivering the bountiful soundsEvergreen trees exude in winter.across my ... Author, Article, and Disclosure InformationAffiliations: From Manhasset, NY 11030.Current Author Address: Joshua Latzman, MD, 321 Thompson Shore Road, Manhasset, NY 11030. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 2 October 2007Volume 147, Issue 7Page: 517KeywordsTea ePublished: 2 October 2007 Issue Published: 2 October 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Value of magnifying endoscopy in classifying colorectal polyps based on vascular pattern
Authors: J. Tischendorf, R. Schirin-Sokhan, K. Streetz, N. Gassler, H. Hecker, M. Meyer, F. Tacke, H. Wasmuth, C. Trautwein, R. Winograd
Journal: Endoscopy (2009)

Narrow-band imaging (NBI) has been developed as a new technique to differentiate tissue patterns in vivo. The aim of this study was to evaluate the diagnostic accuracy of NBI endoscopy with and without high magnification for the differentiation of neoplastic from non-neoplastic colorectal polyps.Among 200 colorectal polyps from 131 patients, 100 lesions were classified according to vascular patterns by NBI endoscopy with high optical magnification and 100 lesions by high-definition endoscopy without high magnification. Additionally, the clarity of the vessel network was assessed. Histologic analysis was performed on all lesions.NBI endoscopy with high magnification resulted in a sensitivity of 92.1 % and a specificity of 89.2 % for the differentiation of neoplastic versus non-neoplastic lesions. This performance was statistically comparable to high-definition NBI endoscopy without high magnification, which showed a sensitivity of 87.9 % and specificity of 90.5 %. However, vessel network was significantly better visualized by NBI endoscopy with optical magnification compared with high-definition NBI endoscopy without high magnification. In comparison with NBI endoscopy, white-light endoscopy, with or without magnification, resulted in inferior discrimination between neoplastic and non-neoplastic polyps.The results demonstrate that the superior visibility of capillary vessels by the NBI technique allows the evaluation of colorectal lesions - based on the vascular patterns - with high diagnostic accuracy. In clinical routine, high-definition NBI endoscopy without high magnification may be used to sufficiently predict colorectal polyp histology, and high magnification can additionally facilitate visualization of vascular networks.
Tuberculosis in India
Authors: Z. F. Udwadia, C. Mehra
Journal: BMJ (2015)

An ancient enemy just gets stronger

Twenty years ago it was widely believed that India was successfully on its way to controlling its alarming tuberculosis (TB) epidemic. The country’s massive scale-up and implementation of directly observed treatment short course (DOTS) therapy under the Revised National Tuberculosis Control Program (RNTCP) was lauded internationally as a global model of excellence. 

Yet this represented only half of the story of TB in India. A terrifying picture of the death, devastation, poverty, and suffering caused by TB began to emerge almost two decades later, when it became apparent that TB in India was not just a national crisis but a global one. Each year India has 2.2 million new cases, more than 300 000 deaths, and economic losses of $23bn (£14.9bn; €20.3bn) from TB,1 making it India’s biggest health crisis. 

At …
Abstract 18396: Diffuse Myocardial Fibrosis Quantification by Cardiac MR is Strongly Associated with B-type Natriuretic Peptide (BNP) and Low Ejection Fraction: Implications for Paradigms of Myocardial Dysfunction
Authors: Erik B Schelbert, William J Ceyrolles, Stephen M Testa, Christopher G Meier, Daniel R Ludwig, Alexander J Blair, Peter Kellman, David Schwartzman, Sanjeev G Shroff, Timothy C Wong
Journal: Circulation (2011)

Background: While myocardial fibrosis has been proposed as the hallmark of pathologic remodeling, its role in myocardial dysfunction is not always recognized in paradigms of cardiac dysfunction. We hypothesized that myocardial fibrosis: 1) would correlate strongly to BNP, a nonspecific and quantitative metric of cardiac dysfunction and potent predictor of outcomes, even after adjustment for key metrics of cardiac changes; and 2) would be prevalent in the setting of cardiac dysfunction. Methods and Results: In 135 patients without myocardial infarction, amyloidosis or hypertrophic cardiomyopathy who were referred for contrast enhanced cardiac magnetic resonance, we quantified the extracellular volume fraction (Ve--a validated and quantitative metric of myocardial fibrosis):Ve = [λ · ρ · (1-hematocrit)] - Vpwhere ρ= specific density of myocardium (1.05), Vp is the myocardial plasma volume fraction (assumed to be a constant 4.5% reflecting capillary density), and λ=[ΔR1 myocardium ] / [ΔR1 bloodpool ] pre and post Gadolinium contrast (where R1=1/T1). T1 was measured with a modified ECG-gated Look-Locker IR-SSFP sequence validated against CuSO4 phantoms. BNP levels were log transformed given their skewed distribution. Elevated Ve was defined as &gt;25%, (above the 99 th percentile in healthy volunteers). In linear regression models, Ve strongly related to ln BNP (unadjusted t value 8.4, p&lt;0.0001, R2=0.35) even after adjusting for ejection fraction (EF), age, sex, diuretic use, myocardial mass index, and body mass index (adjusted t value 4.4, p&lt;0.0001, R2=0.65). Similar data were obtained when circumferential or meridional wall stress was substituted for EF (not shown). In the 40% of patients with EF&lt;50%, 71% had elevated Ve (chi square 24, p&lt;0.0001). In the 45% of patients with BNP&gt;100 pg/mL, 75% had elevated Ve (chi square 24, p&lt;0.0001). Conclusions: Myocardial fibrosis is strongly and independently associated with cardiac dysfunction quantified by BNP levels. Myocardial fibrosis is highly prevalent in those with cardiac dysfunction defined by EF&lt;50% or BNP&gt;100 pg/mL. These data suggest an important role of myocardial fibrosis in human myocardial dysfunction. Paradigms of cardiac dysfunction should include the role of myocardial fibrosis.
Relapse of pneumocystis pneumonia in the upper lobes during aerosol pentamidine prophylaxis.
Authors: M J O'Doherty, S H Thomas, N T Bateman
Journal: Thorax (1989)

Repeatability of ventilatory function measurements in a population survey of seven year old children SIR,-The impression was given by Dr David Strachan (June 1989;44:474-9) that the coefficient of variation for FEV, in seven year old children was low, possibly even lower than that for the vital capacity.We wonder whether this could be a spurious finding.In a recent survey of 120 healthy seven year
Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP Chemotherapy
Authors: RICHARD I. FISHER
Journal: Annals of Internal Medicine (1983)

A new treatment program was developed in an attempt to increase the complete remission rate and survival of previously untreated patients with advanced stages of diffuse aggressive lymphomas. A flexible number of cycles of ProMACE chemotherapy (prednisone, methotrexate, doxorubicin, cyclophosphamide, and epipodophyllotoxin VP-16) was alternated with a flexible number of cycles of MOPP chemotherapy (mechlorethamine, vincristine sulfate, procarbazine, and prednisone), and finally late intensification with ProMACE therapy was given. The duration of each phase of treatment was determined by the patient's rate of tumor response. Complete remissions were achieved in 55 of 74 patients (74%) with a median duration of follow-up exceeding 2 1/2 years. Only ten of the complete responders (18%) have had relapse. The dose-limiting toxicity is myelosuppression, and eight patients (10%) died from sepsis. Median survival for all patients has not been reached but is predicted to exceed 4 years with 65% of patients alive at 4 years. Previously we achieved a 46% complete remission rate with 38% of all patients alive at 4 years; relapse-free survival beyond 2 years was tantamount to cure. Therefore, ProMACE-MOPP chemotherapy represents a substantial improvement in treating patients with diffuse aggressive lymphomas.
Pardon in Brittany
Authors: Thomas B. Cole
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
'Terminal' terminology challenged
Authors: R. M. Wettstein
Journal: JAMA (1978)

To the Editor.—  Bravo to B. J. Kennedy, MD. He deserves front-page headlines for advocating the abolition of the phrase   (239:138, 1978). In days former, such expression was redundant anyway; cancer was untreatable, death imminent. Presently, though, it is simply inaccurate; cancer is not untreatable and death is not imminent.  While such redefinition of cancer as a chronic illness similar to cirrhosis or emphysema, for example, must be initiated by the medical community, it is only our first step. We are then obliged to reeducate the general public in the term's obsolescence, for not just physicians but also laymen, perhaps even more frequently, use the expression. By referring to cancer as a terminal process, people reveal their equation of cancer with imminent death.  Our redefinition will perhaps treat the illness with which both cancer patients and noncancer patients alike suffer—incapacitating fear. Cancerophobia underlies patient delay in seeking medical